ISAR ELections 2019
This year Society members will vote to fill the position of Secretary and three Board of Director seats:
Jinhong Chang, MD, Ph.D., is a Professor and Principal Investigator, Laboratory of Molecular Virology and Antiviral Research, at Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.
Dr. Chang received her medical education and clinical training in Infectious Diseases as well as Ph.D. training in Virology at Peking University Health Science Center, Beijing, China. She received her postdoc training in Molecular Virology at Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Dr. Chang has more than 20 years of research experience in the areas of molecular virology, innate immunity and antiviral drug discovery, and has more than 90 publications in peer-reviewed journals and 6 patents. She established her independent translational research group at Drexel University, Philadelphia, Pennsylvania, in 2007 and joined Baruch S. Blumberg Institute in 2015. Her group has been focused on the development of antiviral and innate immune modulating agents for treatment of viral infections that cause hepatitis and hemorrhagic fever.
Dr. Chang has been a member of the Editorial Board of Antiviral Research since 2015, and will serve as an Editor of Antiviral Research starting November 2018.
Jinhong has been a member of ISAR since 2008. She has participated in reviewing ICAR abstracts for the past 5 years, and has been a member of the ICAR poster award committee since 2015. Dr. Chang served as a mentor for the Woman in Science program in 2016 and 2017.
Dr. Zlatko Janeba earned his Ph.D. in organic chemistry from the Institute of Organic Chemistry and Biochemistry
(IOCB) in Prague. He underwent postdoctoral training in the groups of Prof. Morris J. Robins (Brigham Young University) and Prof. Paul F. Torrance (Northern Arizona University). He spent three years at Moravek Biochemicals,
Inc. in California, and in 2008, he rejoined the research team of Prof. Anton &n Holy´ at the IOCB. He established his Junior Research Group in 2010, and since January 2016, he has been the head of the Senior Research Group at the IOCB. Current research of his group involves design and synthesis of modified nucleosides, nucleotides, and other heterocyclic compounds, with a wide range of biological properties. He is a member of International Society for Antiviral Research, International Society of Nucleosides, Nucleotides and Nucleic Acids, and International Society
of Heterocyclic Chemistry (ISHC). Currently, Dr. Janeba is an associate editor of Antiviral Chemistry & Chemotherapy and serves as vice-chairman of the IOCB supervisory board and of the supervisory board of IOCB TTO.
Board of Directors Candidates
Maaike (pronounced “Micah”) Everts is an associate professor in the Division of Infectious Diseases of the Department of Pediatrics, University of Alabama School of Medicine at Birmingham. She was born in Meppel, the Netherlands.
After receiving a masters degree in pharmaceutical sciences and a PhD in pharmacokinetics and drug delivery from the University of Groningen, she moved to UAB for postdoctoral training with David Curiel in the Division of Human Gene Therapy, where she pursued her interest in targeted gene delivery for the treatment of cancer, using adenoviral vectors. She joined the UAB Department of Pathology in August 2005, continuing her research on targeted therapies using gene therapy and nanotechnology approaches.
Since 2009, Maaike has been the associate director of the Alabama Drug Discovery Alliance, a collaboration between UAB and Southern Research, with the goal of finding new small-molecule drugs for unmet medical needs in a variety of therapeutic areas. She also assists physician-investigators with the IND application process, and provides quality assurance for the UAB Vector Production Facility, which manufactures novel drugs for Phase I clinical trials. She is also the administrative director for the Antiviral Drug Discovery and Development Center, a multi-institutional consortium funded by a U19 grant from NIAID. Maaike joined ISAR in 2015. In 2016 she was invited to join the Women in Science committee and to be responsible for organizing the career development panel.
Prof. Chris Meier, born 1962 in Berlin, Germany, received a diploma and a doctorate (Ph.D.) in Chemistry from the University of Marburg, Germany. During his Ph.D. thesis, he worked in the group of Prof. Gernot Boche on the synthesis of so-called ultimate carcinogens formed from aromatic amines by metabolic steps, metabolites which are involved in the induction of carcinogenesis. He joined the Organic Chemistry Division at the Pasteur-Institute in Paris, France, headed by Prof. Jean Igolen and Prof. Tam Huynh-Dinh as a Post-Doc and started working on nucleoside chemistry and prodrugs. He returned to Germany joining the University of Frankfurt/Main in 1991 as an Assistant Professor under the mentorship of Prof. Joachim Engels. In 1996 he obtained the Habilitation in Organic Chemistry from the University of Frankfurt/Main, Germany. He was appointed as Associate Professor at the University of Würzburg, Germany and then in 1999 he joined University of Hamburg, Germany as a full professor. He is the Scientific Director of the Centre for Structural Systems Biology (CSSB) in Hamburg. Moreover, he is the current President of the International Society on Nucleoside, Nucleotides and Nucleic Acids (IS3NA), after being Vice-President the previous two years. He received the Prusoff-Award in 2007 and the Antonin Holy-Award 2018 from the International Society on Antiviral Research (ISAR). He was involved with ISAR since many years ago, serving as chair of the program committee “medicinal chemistry” and being a long standing member of the poster award committee. Recently, he was awarded as being a Zhiquiang-guest professor from Shanghai University, China, and he has worked as an invited guest professor and visiting professor at the University of Montpellier II and Toulouse, France, and Shanghai, China. His research focuses are pronucleotide development, nucleoside chemistry, structure-based drug design of small molecule antivirals against Bunya viridaeand hemorrhagic fever viruses, carbohydrate chemistry, phosphorylation methods in nucleoside chemistry and the synthesis of photocaged compounds, e.g. second messengers. He has published more than 235 scientific publications and is an inventor of record in 10 issued patents.
Luis Schang is the Director of the Baker Institute of Cornell University College of Veterinary Medicine. He got his Médico Veterinario (Veterinary doctor) degree from the University of Buenos Aires, Argentina in 1987. He then received a Ph.D. on molecular virology from the University of Nebraska Lincoln before doing a postdoctoral training with the late Dr. Schaffer at the School of Medicine of the University of Pennsylvania. He moved to take an assistant professor position at the Faculty of Medicine and Dentistry of the University of Alberta in 2000, where he climbed the ranks to the full professorship and co-led international programs with the Helmholtz Association (Germany) and Zhejiang University before moving to Cornell University in 2016.
Luis attended his first ICAR in 2000 (Baltimore) and has been a member of the publications committee of our society since 2007, of the Poster awards committee since 2014, and of the Ambassador program (South America and Canada) since 2014. He became a co-chair of the publications committee, together with Anthony Vere Hodge, earlier this year and has regularly guest edited ISAR News issues.
Luis is a molecular virologist interested in using chemical biology to learn aboutthe interactions between viruses and infected cells, interactions which determine the outcomes of all infections. He is particularly interested in identifying commonalities among unrelated viruses. Luis’ group works with a number of established human pathogens, including herpes simplex virus 1 and 2 (HSV-1; -2), hepatitis C virus (HCV), and influenza A virus (IAV), and emerging viruses such as Zika virus. With the research team, Luis identifies or designs small molecules that inhibit the infectivity or replication of a variety of unrelated viruses and then uses these compounds as probes to identify commonalities among the affected viruses. This research answers fundamental questions on molecular virology while identifying biologically active small molecule scaffolds that may be developed as antivirals. Using this approach, hisgroup has identified new families of compounds with antiviral activity against multiple unrelated viruses (broad-spectrum antiviral activity), as well as some compounds that act exclusively against single viruses. He is interested the most in compounds with novel targets and mechanisms of action, such as the first lipid targeting antiviral molecules, the RAFIs. His work has resulted in 67 publications and patents issued in the EEUU, the European Union, Canada, China and Japan.
Luis is a member of the editorial board of several journals in the antiviral area, including the official publication of our society, Antiviral Research, as well as Antimicrobial Chemistry and Chemotherapy (ACC) and the Journal of Virology, the official journals of the American Society for Microbiology (ASM). He is also a section editor of PLOS One, and an editor of Virology Journal, and contributes reviewing manuscripts for a number of publications, including PLOS Pathogens, mBio, and eLife among many others. He reviews grants for the NIH, the Canadian Institute of Health Research, and several Argentinean, UK, Polish, Belgian, and Hong Kong agencies, among others.
Dr. Jessica R. Spengler received her M.P.H. in infectious diseases in 2004 from the University of California, Berkeley, and then completed a California Epidemiologic Investigation Service (Cal-EIS) fellowship with the Vector-Borne Disease Section of the California Department of Health from 2004–2005. She received her Ph.D. (2011) and D.V.M. (2012) from the University of California, Davis. Her graduate research on innate immune evasion by hantaviruses was performed on-site with the Special Pathogens Program at the Public Health Agency of Canada in Winnipeg, Manitoba, and at the NIH Laboratory of Virology, Rocky Mountain Laboratories (Hamilton, Montana). Since 2012, Dr. Spengler has worked with the Viral Special Pathogens Branch at the Centers for Disease Control and Prevention in Atlanta, Georgia. Currently, she directs a translational research program utilizing biosafety level 4 laboratory facilities to identify, prevent, ameliorate, and control high-hazard zoonotic viral pathogens, including Ebola, Marburg, Nipah, Crimean-Congo hemorrhagic fever, and Rift Valley fever viruses. This program investigates molecular mechanisms of pathogenesis, develops animal models of disease, and conducts in vivo screens of therapeutic and vaccine candidates for high-containment, high-consequence viral hemorrhagic fevers.
Subhash Vasudevan was born in Singapore (1959). He obtained his BSC Hons in Chemistry (La Trobe University, Australia; 1985) and PhD in Biochemistry from The Australian National University (ANU) in 1989 followed by post-doctoral training at the Max-Planck Institute for Biophysics in Germany and Research School of Chemistry at ANU. He established his first independent research laboratory at James Cook University (Australia) when he was appointed as a lecturer in Biochemistry and Molecular Biology (1993) and rose through the ranks to become a Reader (~Assoc. Professor). It was during this period that he started working on dengue virus focusing mainly on the NS3 and NS5 proteins. In 2003 he moved to Singapore as the inaugural Unit Head of the Dengue Research Unit at the newly established Novartis Institute for Tropical Diseases and led an intensive effort to find directly acting antivirals against dengue virus serotypes. In 2008 he was recruited to the Signature Research Program in Emerging Infectious Diseases at the Duke-National University of Singapore Medical School where he currently pursues his research interests in dengue and zika pathogenesis and antiviral drug discovery and development. He was appointed as an Editor of Antiviral Research (Elsevier) in 2009 and is a member of the Editorial Board of the Journal of Virology (2017-2021).
Recently, Subhash has started to become involved with ISAR to try and increase the membership from Asia and also hopes to attract and help organize together with Griffith University’s Institute for Glycomics, the ICAR in the Gold Coast in Australia in 2021.
The International Society for Antiviral Research (ISAR) is an internationally recognized organization for scientists involved in basic, applied, and clinical aspects of antiviral research. The Society main event is the annual International Conference on Antiviral Research (ICAR), a truly interdisciplinary meeting which attracts the interest of chemists, biologists, and clinicians.